Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Randomised, Placebo-controlled Study of Intravenous Doses of SPL026 (DMT Fumarate), a Serotonergic Psychedelic, in Healthy Subjects (Part A) and Patients With Major Depressive Disorder (Part B)

Next Previous
X
Search
Trial Profile

A Double-blind, Randomised, Placebo-controlled Study of Intravenous Doses of SPL026 (DMT Fumarate), a Serotonergic Psychedelic, in Healthy Subjects (Part A) and Patients With Major Depressive Disorder (Part B)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs N-N-dimethyltryptamine (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Small Pharma

    • Most Recent Events

    • 10 Dec 2024 Results presented in the Cybin Inc Media Release.
    • 10 Dec 2024 According to a Cybin Inc. media release, company announced results from a completed Phase 1b study exploring drug-drug interactions between N,N-dimethyltryptamine and selective serotonin reuptake inhibitors in MDD patients at the American College of Neuropsychopharmacology Annual Meeting taking place December 8-11, 2024, in Phoenix, Arizona.
    • 27 Jul 2023 According a Small Pharma media release, SPL026 Phase IIa clinical trial results well-received at several international scientific conferences

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top